X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (62) 62
humans (49) 49
heterocyclic compounds, 3-ring - therapeutic use (24) 24
heterocyclic compounds, 3-ring - pharmacology (19) 19
hiv infections - drug therapy (18) 18
animals (15) 15
heterocyclic compounds, 3-ring - economics (15) 15
male (15) 15
simeprevir (15) 15
uridine monophosphate - analogs & derivatives (15) 15
heterocyclic compounds, 3-ring - chemistry (14) 14
sofosbuvir (13) 13
adult (12) 12
drug therapy (12) 12
drug therapy, combination (12) 12
antiviral agents - therapeutic use (11) 11
dolutegravir (11) 11
heterocyclic compounds, 3-ring - administration & dosage (11) 11
antiviral agents - economics (10) 10
female (10) 10
infectious diseases (10) 10
pharmacology & pharmacy (10) 10
sulfonamides - economics (10) 10
sulfonamides - therapeutic use (10) 10
toxicology (10) 10
uridine monophosphate - economics (10) 10
uridine monophosphate - therapeutic use (10) 10
analysis (9) 9
antiviral agents (9) 9
chemistry, medicinal (9) 9
food science & technology (9) 9
hepatitis c (9) 9
hepatitis c, chronic - drug therapy (9) 9
heterocyclic compounds, 3-ring - adverse effects (9) 9
hiv (9) 9
human immunodeficiency virus--hiv (9) 9
middle aged (9) 9
molecular structure (9) 9
cost-benefit analysis (8) 8
double-blind (8) 8
heterocyclic compounds, 3-ring - chemical synthesis (8) 8
hiv integrase inhibitors - therapeutic use (8) 8
raltegravir (8) 8
treatment outcome (8) 8
antiretroviral drugs (7) 7
antiretroviral-naive adults (7) 7
article (7) 7
heterocyclic compounds, 3-ring - isolation & purification (7) 7
immunology (7) 7
infection (7) 7
once-daily dolutegravir (7) 7
research article (7) 7
ribavirin (7) 7
acquired immune deficiency syndrome--aids (6) 6
antiretroviral therapy (6) 6
care and treatment (6) 6
chemistry, applied (6) 6
drug resistance (6) 6
economic aspects (6) 6
gastroenterology & hepatology (6) 6
health aspects (6) 6
hepacivirus - drug effects (6) 6
hepatitis c - drug therapy (6) 6
hepatitis c, chronic - economics (6) 6
heterocyclic compounds, 3-ring (6) 6
hiv infection (6) 6
hiv-1 - drug effects (6) 6
integrase (6) 6
metabolites (6) 6
mice (6) 6
microbiology (6) 6
multidisciplinary sciences (6) 6
anti-hiv agents - adverse effects (5) 5
anti-hiv agents - therapeutic use (5) 5
biology (5) 5
cell line, tumor (5) 5
clinical trials (5) 5
derivatives (5) 5
drug discovery (5) 5
efficacy (5) 5
genotype (5) 5
hepacivirus - genetics (5) 5
heterocyclic compounds (5) 5
hiv infections - virology (5) 5
inhibition (5) 5
lamivudine - therapeutic use (5) 5
medicine (5) 5
medicine, general & internal (5) 5
monascin (5) 5
ribavirin - economics (5) 5
ribavirin - therapeutic use (5) 5
safety (5) 5
science (5) 5
therapy (5) 5
young adult (5) 5
abridged index medicus (4) 4
adolescent (4) 4
aids (4) 4
ankaflavin (4) 4
anti-hiv agents - administration & dosage (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 58, Issue 7, pp. 928 - 936
Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs... 
sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | POTENT | BI 201335 | HIV | INHIBITOR | ANTIRETROVIRAL TREATMENT | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Hepacivirus | Sofosbuvir | Economic aspects | Antiviral agents | Production management | Care and treatment | Hepatitis C | and Commentaries
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 07/2015, Volume 62, Issue 6, pp. 784 - 791
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145885
Objectives To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and... 
ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EFFICACY | SAFETY | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | MARAVIROC | OPTIMIZED BACKGROUND THERAPY | ANTIRETROVIRAL-NAIVE ADULTS | HIV Integrase Inhibitors - pharmacology | Heterocyclic Compounds, 3-Ring - economics | Quality-Adjusted Life Years | HIV-1 - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Drug Resistance, Viral | HIV-1 - physiology | Cost-Benefit Analysis | Heterocyclic Compounds, 3-Ring - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Adult | HIV Infections - drug therapy | France | Monte Carlo Method | HIV Integrase Inhibitors - economics | Infection | Highly active antiretroviral therapy | Antiviral agents | Medical research | Algorithms | Economic aspects | Markov processes | Medicine, Experimental | HIV patients | Comparative analysis | HIV (Viruses) | Health aspects | Costs | Opportunist infection | Markov chains | Infections | Family medical history | Population genetics | Utilities | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Drug therapy | Age | Integrase | Monte Carlo method | Antiretroviral drugs | Sensitivity analysis | Life expectancy | Computer simulation | Patients | Antiretroviral therapy | CD4 antigen | Life span | Adults | Cost analysis | Monte Carlo simulation | Markov process | Acquired immune deficiency syndrome | AIDS | HIV | Markov models | Human immunodeficiency virus
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9946, pp. 853 - 853
Journal Article
American Journal of Public Health, ISSN 0090-0036, 03/2015, Volume 105, Issue 3, pp. 457 - 463
Patients with chronic HCV have predictable overlapping comorbidities that reduce access to care. The Affordable Care Act (ACA) presents an opportunity to focus... 
IMPROVING PRIMARY-CARE | INJECTION-DRUG USERS | COST-EFFECTIVENESS | SUBSTANCE-ABUSE | COLLABORATIVE CARE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HEPATITIS-C VIRUS | CHRONIC ILLNESS | COMMUNITY-HEALTH CENTERS | ANTIRETROVIRAL THERAPY | HIV-INFECTED PATIENTS | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | United States - epidemiology | Prevalence | HIV Infections - epidemiology | Humans | Hepatitis B - epidemiology | Drug Approval | Uridine Monophosphate - economics | Health Services Accessibility - economics | Insurance Coverage - legislation & jurisprudence | Adult | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Insurance Coverage - economics | Mental Disorders - epidemiology | Poverty | Antiviral Agents - therapeutic use | Comorbidity | Patient Protection and Affordable Care Act - standards | Risk Factors | Substance Abuse, Intravenous - epidemiology | Genotype | Health Services Accessibility - legislation & jurisprudence | Patient Protection and Affordable Care Act - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Population Surveillance | Health Services Accessibility - trends | Sofosbuvir | Care and treatment | United States | Medical care | Management | Hepatitis C | Risk factors | Public health | Hepatitis | Disease management | Drug therapy | Mortality | Patient Protection & Affordable Care Act 2010-US | Health Policy | Windows of Opportunity | Opioids | Health Reform
Journal Article
The Lancet HIV, ISSN 2352-3018, 03/2018, Volume 5, Issue 3, pp. e146 - e154
There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy... 
DIAGNOSIS | INFECTIOUS DISEASES | ANTIRETROVIRAL THERAPY | DOLUTEGRAVIR | INFECTION | IMMUNOLOGY | CARE
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 06/2018, Volume 57, Issue 24, pp. 7181 - 7185
Dolutegravir (DTG), an important active pharmaceutical ingredient (API) used in combination therapy for the treatment of HIV, has been synthesized in... 
amidation | continuous flow | multistep synthesis | HIV | pyridone | ORGANIC-SYNTHESIS | PHARMACEUTICALS | EMTRICITABINE | NON-INFERIORITY TRIAL | INITIAL TREATMENT | CHEMISTRY, MULTIDISCIPLINARY | TENOFOVIR ALAFENAMIDE | DOUBLE-BLIND | INFECTION | CHEMISTRY METHODS | BICTEGRAVIR | Combinatorial Chemistry Techniques - methods | Amides - chemical synthesis |